Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of abicipar in patients with Diabetic macular edema (DME)

Trial Profile

Phase III study of abicipar in patients with Diabetic macular edema (DME)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abicipar pegol (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors AbbVie; Allergan

Most Recent Events

  • 09 May 2019 According to a Molecular Partners AG media release, Allergan plans to launch this trial in 2020.
  • 07 Feb 2019 According to a Molecular Partners AG media release, Allergan intends to initiate this study in H2 2019.
  • 08 Feb 2018 According to a Molecular Partners AG media release, company expects to initiate this trial in H2 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top